Stockwinners Market Radar for February 13, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:55 EST Monolithic Power CEO sells $3.12M in common stock - In a regulatory filing, Monolithic Power disclosed that its CEO sold 6.3K shares of common stock on February 13th in a total transaction size of $3.12M.

20:21 EST Fusion Pharmaceuticals jumps 39% after buying prostate cancer detection assets - Shares of Fusion Pharmaceuticals were up 39% or $1.40 afterhours at $5.02 after the company announced that it is buying the investigational new drug application for an ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T from RadioMedix.

20:09 EST Cathie Wood's ARK Investment bought 118.7K shares of Coinbase today

19:13 EST Norfolk Southern says continuing to address East Palestine derailment - Norfolk Southern said it is continuing to work with local, state, and federal leaders and the community affected by the derailment in East Palestine, OH on February 3. Additionally, Norfolk Southern would like to update its customers on the status of railroad operations. "Both mainlines were restored to service on February 7 - after our Engineering team and contractors worked to quickly clear the site and laydown new infrastructure," the company said. "Norfolk Southern continues to make progress in two key areas: addressing the backlog of traffic; and getting power and crews back in cycle. As we continue to do so, customers will see a positive reflection of these efforts in the status of their shipments."

18:58 EST RxSight director buys $6.0M in common stock - In a regulatory filing, RxSight disclosed that its director Juliet Tammenoms Bakker bought 480K shares of common stock on February 10th in a total transaction size of $6.0M.

18:06 EST Manhattan Associates CEO sells $2.07M in common stock - In a regulatory filing, Manhattan Associates disclosed that its CEO Eddie Capel sold 250.1K shares of common stock on February 9th in a total transaction size of $2.07M.

18:02 EST Axcelis director sells $1.52M in common stock - In a regulatory filing, Axcelis disclosed that its director Thomas St. Dennis sold 12K shares of common stock on February 13th in a total transaction size of $1.52M.

17:51 EST AEP, Liberty file new FERC 2023 application for approval of Kentucky sale - American Electric Power and Liberty, an indirect subsidiary of Algonquin Power & Utilities Corp., filed a new application with the Federal Energy Regulatory Commission under section 203 of the Federal Power Act seeking approval of the sale of AEP's Kentucky operations to Liberty. The companies are asking FERC for expedited review of the application as they work to close the transaction by April 26, 2023. In December 2022, FERC denied approval of the sale without prejudice and outlined the additional information about customer protections needed to obtain approval. "AEP and Liberty are committed to the sale and are requesting FERC's accelerated review of the application so customers in eastern Kentucky can begin benefiting from the transaction," said Julie Sloat, AEP president and chief executive officer. "In addition to the Kentucky sale, AEP remains focused on advancing the strategic initiatives we have outlined, including the sale of our competitive renewables portfolio and the strategic review of our retail business. These actions are consistent with the equity financing plan, operating earnings guidance and long-term growth rate of 6-7% announced at our analyst day last October."

17:35 EST VP of United Airlines Kenny sells $783K in company shares - VP of United Airlines Chris Kenny disclosed in a regulatory filing that he had sold 16,000 shares of company stock at $48.94 per share on February 10, for a total transection amount of $783,070.

17:21 EST MacroGenics to present clinical results from Lorigerlimab study at ASCO - MacroGenics "announced preliminary safety and anti-tumor activity data from the dose expansion phase of the Company's ongoing Phase 1 clinical trial of lorigerlimab, a bispecific, tetravalent PD-1 CTLA-4 DART(R) molecule. This investigational molecule was designed to block PD-1 with enhanced CTLA-4 blockade on dual PD-1/CTLA-4-expressing cells, such as tumor-infiltrating lymphocytes, while maintaining maximal PD-1 blockade on all PD-1-expressing cells. The preliminary data is being presented in a poster titled "Lorigerlimab, a Bispecific PD-1 CTLA-4 DART Molecule in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Expansion Cohort" at the American Society of Clinical Oncology Genitourinary Cancers Symposium taking place February 16-18, 2023, in San Francisco, CA. As of the December 12, 2022 data cut-off, 118 patients with mCRPC, melanoma, non-small cell lung cancer or microsatellite-stable colorectal cancer were enrolled in the cohort expansion phase of the lorigerlimab Phase 1 study at the dose of 6.0 mg/kg, administered intravenously every three weeks."

17:04 EST BioXcel announces seven patients achieve composite response in BXCL701 trial - BioXcel Therapeutics announced full data from its Phase 2a trial of BXCL701, the company's investigational, oral innate immune activator, in combination with Keytruda in small cell neuroendocrine, or SCNC, variant metastatic castration-resistant prostate cancer, or mCRPC, patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer. Results will be presented in a rapid abstract presentation and a poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers, or ASCO GU, Symposium on February 16. In the evaluable patient cohort, seven patients achieved a composite response, the primary endpoint of the trial. In patients with RECIST 1.1-defined measurable disease, partial response was observed in five patients. The disease control rate, defined as complete response + partial response + stable disease, was 48%. The median duration of response for both composite responses and RECIST 1.1-defined partial responses was 6+ months as of the data cutoff on December 19, 2022. Six out of 34 patients in the safety population experienced serious adverse events, or SAEs, possibly related or related to BXCL701 or pembrolizumab, and six patients discontinued any drug due to a treatment-related AE. No evidence found that BXCL701 potentiates immune-related AEs related to immune checkpoint inhibitors. DPP9 overexpression was identified as a potential predictive biomarker for BXCL701 response; biomarker evaluation is ongoing and additional findings will be presented at an upcoming medical meeting.

17:00 EST Callon Petroleum board chair Richard Flury to retire - Callon Petroleum Company announced L. Richard Flury's intention to retire from the Board of Directors following the 2023 Annual Meeting of Shareholders. "With guidance from Richard's deep experience in the energy industry, Callon has built a high-quality asset base of more than 200,000 gross acres in the leading oil plays in the Permian Basin and Eagle Ford Shale that has allowed us to profitably grow our production throughout his tenure," commented Callon President and Chief Executive Officer Joe Gatto. "Richard's leadership supported Callon through transformational acquisitions that have positioned the Company to execute our "Life of Field" Co-Development model on a deep inventory of high-return projects while preserving balance sheet strength. In addition, his focus on good governance has resulted in a strong and diverse Board that will continue to pursue sustainable value for all stakeholders. We are deeply appreciative of Richard's enduring contributions to the Company and wish he, Liz and their family all the best." Mr. Flury has served as director of the Company for nineteen years and as Board Chair since 2017. Prior to joining the Board, he spent a 30-year career with BP plc and predecessor entities in roles of increasing responsibility including as Chief Executive for Gas, Power and Renewables. Mr. Flury's previous board service includes McDermott International, Chicago Bridge and Iron Company where he served as board chair, and QEP Resources, Inc. In preparation for Mr. Flury's forthcoming retirement, the Board has named independent director Matthew R. Bob as Chair-elect and expects to appoint him as Chair immediately following the upcoming Annual Meeting. Mr. Bob has served on the Callon Board since 2014 and is currently Chair of the Compensation Committee. He recently retired as President of Eagle Oil & Gas Co., an independent oil and gas company with operations in Texas. A registered geoscientist, he is also the founder and managing member of MB Exploration, LLC. Mr. Bob previously served as a director of Southcross Energy Partners, a natural gas processing and transportation company in South Texas, prior to its acquisition by Targa Resources Corp.

16:54 EST Cleveland-Cliffs sees $100 per ton boost in selling price for auto in 2023 YoY - On December 22, Cliffs announced that it had successfully renewed a large portion of its fixed price contracts, and expected a $100 per ton selling price increase for its direct automotive business in 2023 compared to 2022. After additional successfully completed negotiations, the Company now expects a $115 per ton increase on these contracts. This end market represents normalized demand of approximately 5M net tons per year. The Company expects an approximately $2B reduction in Steelmaking COGS in 2023 compared to 2022. The primary drivers of this significant reduction in costs are normalized repair and maintenance expenses, higher production volume and lower input costs.

16:46 EST Elastic names Mathew Donoghue Chief Marketing Officer - Elastic appointed Mathew Donoghue as Chief Marketing Officer effective February 13. Prior to joining Elastic, Donoghue spent 15 years managing marketing strategy and execution. Most recently, Donoghue served as Senior VP, Global Marketing at Palo Alto Networks.

16:43 EST InterPrivate III Financial Partners to transfer listing to NYSE American - InterPrivate III Financial Partners announced that it will transfer its listing from the New York Stock Exchange to the NYSE American LLC. InterPrivate received written confirmation that it received the final approval for listing from the staff of NYSE American on February 13, 2023. In connection with the transfer, InterPrivate will voluntarily delist from the New York Stock Exchange, and expects to begin trading on the NYSE American on or about February 16, 2023. InterPrivate's decision to transfer to the NYSE American was made to permit the continued listing of its securities following recent redemptions of InterPrivate's Class A common stock in connection with the vote to extend the deadline by which InterPrivate must complete its initial business combination. Following the transfer to the NYSE American, InterPrivate intends to continue to file the same types of periodic reports and other information it currently files with the U.S. Securities and Exchange Commission.

16:35 EST Fusion Pharmaceuticals trading resumes

16:33 EST United Community Banks to acquire First Miami for $115.9M, sees accretion - United Community Banks (UCBI) and First Miami Bancorp announced the execution of a definitive merger agreement pursuant to which United will acquire First Miami, and its wholly-owned subsidiary, First National Bank of South Miami in an all-stock transaction with an aggregate value of approximately $115.9M, or $1,330 per share of First Miami common stock, based on United's 10-day average closing stock price of $33.02 as of February 10. Additionally, First Miami shareholders will receive a special cash dividend at closing from net proceeds of the sale of certain investment securities held by First Miami. FNBSM is headquartered in South Miami, Florida, and operates three offices in the Miami metropolitan area. As of December 31, 2022, FNBSM had total assets of $1B, total loans of $594M, and total deposits of $867M. In addition to traditional banking services, FNBSM offers private banking, trust and wealth management services and has approximately $310M in assets under management. FNBSM is well-known in its local communities and has focused on steady, high-quality growth by hiring and developing a skilled banking team. Under the terms of the merger agreement, First Miami shareholders will receive 40.2685 shares of United common stock for each share of First Miami common stock outstanding. The merger is expected to be accretive to United's earnings per share, excluding transaction costs, by approximately 9c per share, or 3% in 2024. The estimated transaction returns are consistent with United's stated acquisition criteria pertaining to tangible book value and targeted internal rates of return. The merger agreement was unanimously approved by the boards of directors of First Miami and United. The merger is expected to be completed in the third quarter of 2023 and is subject to customary conditions, including regulatory approval as well as the approval of First Miami's shareholders.

16:31 EST Allison Specialty Series transmissions selected for U.S. Army vehicles - Allison Transmission announced that Allison's 4000 Specialty Series transmissions are included in the U.S. Army's Common Tactical Truck prototype vehicle phase. CTT, the newest tactical wheeled vehicle program, will begin replacing the U.S. Army's aging fleet of heavy tactical wheeled vehicles. The U.S. Army has proposed replacing most variants in its heavy tactical wheeled vehicle fleet with a single platform that shares a common powertrain, chassis and cab. The Army selected four companies to each provide several different prototype vehicles to refine specifications as the program moves to vehicle testing in 2024 and initial production by 2027. "Allison Transmission is committed to leveraging advancements made in the commercial vehicle industry to provide defense customers with fuel efficient, reliable and innovative propulsion solutions," said Dana Pittard, Vice President, Defense Programs, Allison Transmission. "System and vehicle level integration expertise is a core competency and differentiator for Allison, and we are proud to deliver next generation capabilities in partnership with our defense customers to optimize vehicle performance for the men and women of our nation's armed forces."

16:30 EST FirstEnergy raises targeted dividend payout ratio to 60%-70% - FirstEnergy announced a new dividend policy that raises the targeted dividend payout ratio to 60% to 70% of operating earnings, from the previous range of 55% to 65%. While all dividend declarations are subject to board approval, the company expects to resume dividend growth for dividends payable later this year. "We recognize the importance of an attractive dividend, and we're pleased to move forward with a new policy that reflects the steps we've taken to improve our credit profile, our confidence in our long-term growth prospects and our commitment to increase value for shareholders," CEO Somerhalder said.

16:24 EST Proterra appoints Julian Soell as COO, Chris Bailey as Chief Business Officer - Proterra announced the appointments of Julian Soell as Chief Operating Officer and Chris Bailey as Chief Business Officer effective March 1. "Julian and Chris are skilled executives who in their new roles will drive greater operational and financial rigor across our entire organization. With their proven track records of execution at our company, I'm looking forward to building on our foundation as we focus on sustainable growth to meet the opportunities ahead for zero-emission transportation," said Proterra CEO Gareth Joyce. As Chief Operating Officer, Julian will oversee all of Proterra's manufacturing and plant operations, quality, and supply chain across the Company's business units that includes Proterra Transit and Proterra Powered & Energy. In his role as Chief Business Officer, Chris will lead all commercial activities for Proterra including business development, sales and marketing, customer program management, as well as customer success and service.

16:21 EST FaZe Holdings announces collaboration with A BATHING APE - FaZe Holdings announced their first official collaboration with global street fashion brand, A BATHING APE. The collection will feature a wide array of co-branded FaZe Clan x BAPE clothing and accessories including t-shirts, sweatsuits, hockey jerseys, gadget pouch, hats and more.

16:21 EST Core & Main to acquire Landscape & Construction Supplies LLC, terms not stated - Core & Main has entered into a definitive agreement to acquire substantially all of the assets of Landscape & Construction Supplies LLC, a full-service provider of geosynthetics products, with two locations in the Chicago metropolitan area.

16:19 EST Fusion Pharmaceuticals to acquire Phase 2 program for prostate cancer candidate - Fusion Pharmaceuticals acquired from RadioMedix the investigational new drug application for an ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen expressed on prostate cancers. Following the closing, the alpha-emitting radiopharmaceutical being evaluated in the TATCIST trial will be known as FPI-2265. Fusion plans to expand the Phase 2 program to additional sites and expects to report data on 20 to 30 patients in the 1Q24. In connection with the closing of the acquisition of the TATCIST trial and related assets, Fusion has agreed to sell an aggregate of approximately 17.6 million common shares to certain accredited institutional investors in a private placement in public equity financing. The offering is expected to result in gross proceeds to Fusion of approximately $60.0M, before deducting placement agent fees and other offering expenses payable by Fusion. At the closing of the offering, Fusion will issue approximately 17.6 million of its common shares at a price of $3.40 per share. The closing of the offering is expected to occur on or about February 16. Upon the closing of the offering, Fusion anticipates having $248.0M in cash and cash equivalents, which it believes will be sufficient to fund its planned operating expenses and capital expenditure requirements into 1Q25.

16:19 EST ICF International awarded $29M contract from NYSDOT - The New York State Department of Transportation recently awarded ICF a $29M contract to develop an equitable and accessible transportation mobility services program through technological innovations. The recompete contract for ICF has a term of five years with an option to extend for one additional year.

16:18 EST EQT Corporation announces planned CFO transition - EQT Corporation announced the planned transition of David Khani, Executive Vice President and CFO, effective in July. EQT will be conducting a search to identify a successor and Khani will work closely with the Board to ensure a smooth transition of leadership.

16:14 EST Parsons to help deliver NYDOT Hunts Point Interstate Access Improvement Project - Parsons announced that the company will help deliver New York State Department of Transportation's Hunts Point Interstate Access Improvement Project, Contract 3 as Lead Designer to the joint venture of El Sol Contracting and Construction Corporation and Defoe Corporation. The $446M design build project will replace the aging structures and improve operations of the existing infrastructure, increase through traffic speeds, update roadway alignments, and expand overall throughput. The effort will improve travel through the corridor by increasing the number of through-lanes on the elevated Bruckner Expressway, at-grade improvements to Bruckner Boulevard, and converting ramps between the Bruckner Expressway and Sheridan Boulevard to right-hand movements. The project will help enhance pedestrian access to the area with a modern shared used path and the replacement of a pedestrian bridge that crosses Bruckner Boulevard to improve safe access to public school PS75. Additionally, a new 117-spot parking lot with 24 electric vehicle, or EV, charging stations, including four rapid charge spots to better accommodate EV drivers, will be constructed under the Bruckner Expressway and help advance the region's sustainability and air quality goals.

16:11 EST Equity Commonwealth announces $4.25 per share special dividend - Equity Commonwealth announced that its Board of Trustees has declared a special, one-time cash distribution of $4.25 per common share which will be paid on March 9, 2023 to shareholders of record on February 23, 2023.

16:09 EST iRobot reducing workforce by 7% - iRobot has initiated a new restructuring program that is expected to deliver net annualized savings of approximately $14M. As part of this restructuring, the company plans to reduce its workforce by approximately 7%, or approximately 85 employees, primarily by streamlining certain functions across the company. In addition to the reduction in force, iRobot's 2023 operating plan incorporates scaled back working media and other demand-generation activities, limited investment in non-robotic product categories and minimal new hiring plans in 2023. In conjunction with the workforce reduction, iRobot expects to record restructuring charges of approximately $4M in 1Q23. The company anticipates that the decline in 2023 GAAP and non-GAAP operating expenses will range from mid-single digits to low double-digits on a percentage basis from 2022 GAAP and non-GAAP levels.

16:06 EST nCino says DOJ investigation closed, no fines or penalties imposed - In a regulatory filing, nCino stated: "As previously disclosed, on February 23, 2021, the company and certain of its officers and other employees were served with grand jury subpoenas wherein the Antitrust Division of the Department of Justice was seeking documents and information in connection with an investigation of the company's hiring and wage practices under US federal antitrust laws. On February 8, 2023, the DOJ informed the company that the investigation is closed. No fines, sanctions, actions, or penalties were imposed or taken against the company or its officers or other employees in connection with this matter, and the costs the company was incurring cooperating with the investigation have now ceased."

16:04 EST MDxHealth: UnitedHealth to provide commercial coverage for GPs test - MDxHealth (MDXH) announced that UnitedHealthcare (UNH) will cover the mdxhealth Genomic Prostate Score GPS test ( under UnitedHealthcare's commercial policies to assist with treatment decisions for individuals newly diagnosed with localized prostate cancer and meeting coverage criteria.Michael K. McGarrity, CEO of mdxhealth, commented: "We are very pleased to announce that UnitedHealthcare, the largest private health insurer in the United States, will provide coverage for our Genomic Prostate Score test. We applaud UnitedHealthcare's decision to identify our GPS test as its only commercially-covered diagnostic that can improve clinical outcomes for men newly diagnosed with localized prostate cancer."In its technical assessment of commercially available genomic panels for stratifying risk in individuals with prostate cancer, UnitedHealthcare's updated Medical Policy cites findings that "the body of evidence consistently favors use of the GPS assay to assist with management strategies..." UnitedHealthcare's commercial coverage of GPS supplements coverage that GPS has from other national and regional commercial payers, as well as from Medicare and Medicare Advantage plans.

16:01 EST Fusion Pharmaceuticals trading halted, news pending

15:42 EST Capital World Investors discloses 7.8% stake in Peloton - Capital World Investors, a division of Capital Research and Management Company, as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited, is deemed to be the beneficial owner of 24,473,268 shares, or 7.8%, of the 313,517,712 shares believed to be outstanding of Peloton Interactive, according to a filing with the SEC.

14:43 EST Aesther Healthcare Acquisition Corp trading resumes

13:51 EST Accenture acquires Morphus, terms not disclosed - Accenture has acquired Morphus, a privately held Brazil-based cyber defense, risk management and cyber threat intelligence services provider, expanding its practice capabilities in Brazil and Latin America. Financial terms were not disclosed. "Together with the capabilities and experienced leadership of Morphus, we will work as one team to help organizations build a cyber resilient business and better secure their digital core, their technology and supply chains," said Paolo Dal Cin, who leads Accenture Security globally. "The acquisition brings more than 230 highly skilled professionals, making Accenture one of the largest cybersecurity professional services providers in Brazil. Our clients are always looking for the best solutions to strengthen their cyber defenses, and the addition of Morphus expands our global research workforce and network of talented, innovative security professionals."

13:38 EST Axsome received Paragraph IV certification notice on Auvelity ANDA from Teva - In a regulatory filing earlier, Axsome Therapeutics (AXSM) disclosed that on February 10, the company received a Paragraph IV Certification Notice Letter from Teva Pharmaceuticals (TEVA), providing notification to the company that Teva has submitted an Abbreviated New Drug Application, or "ANDA," to the U.S. Food and Drug Administration seeking approval to manufacture, use, or sell a generic version of Auvelity, or dextromethorphan HBr-bupropion HCl. "In the Notice Letter, Teva alleges that four of the patents listed in the FDA Orange Book for Auvelity, U.S. Patent Numbers 10,780,064; 10,925,842; 10,940,124; and 10,966,942, each of which expires in 2040, are invalid, unenforceable, or will not be infringed by Teva's manufacture, use, or sale of the generic product described in its ANDA submission. The Paragraph IV Certification does not challenge any of the remaining Orange Book listed patents for Auvelity which have expirations out to 2034," Axsome stated in the filing.

12:58 EST Carlisle CFO Zdimal sells 8,111 common shares - In a regulatory filing, Carlisle Companies VP and CFO Kevin Zdimal disclosed the sale of 8,111 common shares of the company on February 10 at a price of $253.35 per share.

12:03 EST ReNew Energy to rebrand as ReNew - ReNew Power has made a strategic decision to rebrand itself as ReNew. The new brand identity reflects the company's transition from being a pure-play renewable Independent Power Producer to an end-to-end provider of solutions across the decarbonisation spectrum. In line with its strategy to focus on the overall clean energy eco-system, ReNew has been leading the development of emerging decarbonisation solutions like green hydrogen, energy storage, carbon markets, and solar manufacturing, and is poised to further the Net-Zero transition goals of enterprises.

12:00 EST FIS falls -13.8% - FIS is down -13.8%, or -$10.44 to $64.99.

12:00 EST Compass rises 12.2% - Compass is up 12.2%, or 45c to $4.15.

12:00 EST Bakkt to discontinue consumer-facing app - Bakkt Holding announced that it is furthering its focus on providing scalable business-to-business technology solutions and will be sunsetting its consumer-facing app. Bakkt will continue its core focus of providing businesses with crypto and loyalty experiences for their customers through SaaS and API solutions on a secure and compliant platform. In November 2022, Bakkt entered into a definitive agreement to acquire Apex Crypto from Apex Fintech Solutions, Inc. Apex Crypto, a turnkey platform for integrated crypto trading, provides services to more than 30 signed fintech partners, serving more than 5 million customers. The pending Apex Crypto acquisition further affirms Bakkt's B2B2C approach and go-forward strategy of bringing crypto products to a broad universe of client verticals. Current Bakkt App users will retain access to all their crypto and cash on the Bakkt platform via a new web experience that is accessible from all devices. Users will still be able to view crypto balances, access crypto transaction reports for tax purposes. The app will officially sunset on March 16. 2023.

11:52 EST Saia LTL Freight opens new terminals in West Virginia - Saia announced that Saia LTL Freight has opened new terminals in both Morgantown and Princeton, West Virginia. With the addition of these two locations, the company now operates three facilities within the state as it continues to focus on building density in its network to provide customers with more direct shipping points.

11:40 EST Meta Platforms Chief Business Officer Marne Levine leaving comapny - Meta Platforms Chief Business Officer Marne Levine announced that she will be leaving Meta after 13 years at the company where she held multiple leadership roles, Meta reported. "She will stay on until the summer to ensure a seamless transition. Moving forward, Nicola Mendelsohn and Justin Osofsky are taking on expanded roles as our most senior sales and partnership leaders, representing the company with our advertisers and partners and reporting to COO Javier Olivan. This new structure continues to bring our business and product teams closer together and helps them operate even more effectively to serve our clients," the company stated in a post to its corporate newsroom. Reference Link

11:04 EST Mattel to relaunch Barney franchise - Mattel announced its relaunch of the iconic Barney franchise. Mattel's comprehensive revitalization of the Barney brand will span television, film, and YouTube content as well as music and a full range of kids' products including toys, books, clothing, and more. Apparel and accessories for adult fans, featuring classic Barney, are also in development. Mattel will relaunch Barney to a new generation with a brand-new animated series, set to debut globally in 2024.

10:41 EST Axsome Therapeutics receives CRL from FDA regarding NDA for AXS-07 - Axsome Therapeutics announced that the Company has received a Complete Response Letter, or CRL, from the U.S. Food and Drug Administration regarding its New Drug Application, or NDA, for AXS-07 for the acute treatment of migraine. The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval of AXS-07. The principal reasons given in the CRL relate to chemistry, manufacturing, and controls considerations. The CRL identified the need for additional CMC data pertaining to the drug product and manufacturing process. Axsome believes that the issues raised in the CRL are addressable and intends to provide potential timing for a resubmission following consultation with the FDA. "It is our goal to work with the FDA to fully understand and adequately address their comments, so that we can make this important new medicine available to patients with migraine as quickly as possible," said Herriot Tabuteau, Chief Executive Officer of Axsome. "The approval of AXS-07 would offer a much-needed new multi-mechanistic treatment option for the millions of people living with this debilitating neurological condition."

10:37 EST WSFS Financial identifies final four banking locations for consolidation - WSFS Financial Corporation announced the final network optimization plan associated with its combination with Bryn Mawr Trust, identifying the final four banking locations to be consolidated later this year. As part of the combination WSFS committed to closing 40 banking office locations, 34 of which were consolidated at bank systems conversion in March 2022, followed by two closures in August 2022. Based on additional reviews of transaction activity and the Bank's broader Retail network, the following final four locations will officially close at 3:00 p.m. on May 24, 2023. Edgmont, 5000 West Chester Pike, Newtown Square, Pa.; Willow Grove, 155 New York Road, Willow Grove, Pa.; Riverton, 712 Broad Street, Riverton, N.J.; Mount Holly, 555 High Street, Mount Holly, N.J. All WSFS Associates currently at these four locations will be assigned to nearby banking offices.

10:04 EST Network-1 subsidiary receives U.S. patent expanding HFT patent portfolio - Network-1 Technologies announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,575,381 to its wholly-owned subsidiary. The claims in the newly issued patent are generally directed toward certain advanced technologies relating to high frequency trading. The newly issued patent arises from a patent application contained in the HFT patent portfolio acquired by HFT Solutions in March 2022. The HFT Patent Portfolio relates to, among other things, technologies used by firms engaged in high frequency trading activities that utilize custom field-programmable gate array hardware, including clock domain management technology that provides critical transaction latency gains in trading systems where the difference between success and failure may be measured in nanoseconds. With this latest issuance, the HFT Patent Portfolio now includes nine issued U.S. patents and two pending U.S. patent applications. The patent terms of the HFT Patent Portfolio are currently expected to extend until 2039. HFT Solutions anticipates further issuances of additional claims for the HFT Patent Portfolio.

10:00 EST TreeHouse falls -6.1% - TreeHouse is down -6.1%, or -$2.93 to $45.40.

10:00 EST ProShares UltraShort Bloomberg Natural Gas rises 10.4% - ProShares UltraShort Bloomberg Natural Gas is up 10.4%, or $5.90 to $62.53.

10:00 EST Fastly rises 19.1% - Fastly is up 19.1%, or $1.89 to $11.76.

09:47 EST Greenhill & Co. falls -6.1% - Greenhill & Co. is down -6.1%, or -72c to $11.13.

09:47 EST FIS falls -13.1% - FIS is down -13.1%, or -$9.91 to $65.52.

09:47 EST Fastly rises 11.2% - Fastly is up 11.2%, or $1.11 to $10.98.

09:45 EST Luxor Capital files proxy materials to oppose Ritchie Bros., IAA merger - Luxor Capital Group, LP , as the manager of funds owning 4.7 million shares of Ritchie Bros. Auctioneers Incorporated (RBA), representing approximately 4.2% of the Company's outstanding shares, announced they have filed their definitive proxy statement with the U.S. Securities and Exchange Commission and sent a letter to the company's shareholders highlighting significant concerns with the proposed merger with IAA, Inc (IAA). Douglas Snyder, President of Luxor, commented: "As the RBA management team continues its attempts to push through this self-serving, ill-advised merger with IAA despite the negative market and shareholder reaction, we cannot sit idly by watching shareholder value destroyed. This deal demonstrates the Company's reckless disregard for shareholders and causes us to further question whose interests are being protected."

09:37 EST Twilio names Aidan Viggiano as CFO, effective March 1 - On February 10, 2023, the Board appointed Aidan Viggiano as the company's CFO effective March 1, 2023. Ms. Viggiano will also serve as the company's principal financial and accounting officer, effective March 1, 2023. Viggiano has served as the company's Senior Vice President of Finance since November 2021. In connection with the Reorganization, the Board appointed Khozema Shipchandler as President, Twilio Communications, effective March 1, 2023. Shipchandler has been serving as the company's COO since October 2021, in addition to serving as principal financial and accounting officer. On February 10, 2023, in connection with the Reorganization, the company's board of directors appointed Elena Donio as President, Twilio Data & Applications, effective March 1, 2023. Donio has been serving as the company's President of Revenue since May 2022.

09:35 EST Twilio sees Q4 results 'at or above' previously provided guidance ranges

09:34 EST Twilio board approves formation of two business units - On February 10, 2023, the Board approved a reorganization of the company's business into two business units: Twilio Data & Applications and Twilio Communications, Twilio said in a regulatory filing. The company believes that the Reorganization will strategically realign the business to promote efficient and accelerated growth.

09:33 EST Twilio announces workforce reduction plan, cutting 17% of workforce

09:26 EST Advent Technologies receives new order from German State of Brandenburg - Advent Technologies announced that it has received a new order from the German State of Brandenburg for its methanol-powered fuel cell systems as part their three-year agreement which was announced in September 2022. The combined value of the Serene fuel cell systems sold to the German State of Brandenburg now totals approximately $1.6M. Advent's methanol-powered fuel cell systems have been chosen as the back-up power source for the German State of Brandenburg's BOS digital radio network. The fuel cell systems will replace the diesel-driven emergency power systems at several sites, providing a more sustainable and reliable emergency power supply solution. The installations relating to the earlier order will be commissioned within the next three months, with the full roll-out of installations set to take place throughout 2023. Advent's fuel cells were selected through a tender launched by the German State of Brandenburg in 2022, which sought sustainable and reliable emergency power supply solutions. The BOS digital radio network covers 99.2% of German territory and provides secure communication for first responders and other public safety officials. The network was developed to replace the outdated analogue radio system used for communication in Germany's old public safety and security infrastructure. Serene fuel cells deliver reliable power in an environmentally friendly manner, reduce CO2 emissions and operate silently, with minimal impact on the surroundings. The use of methanol as a carrier of hydrogen allows for simpler storage than pure hydrogen and enhances the safety of operations. Serene fuel cells offer the potential for a reduction of more than 80% in CO2 emissions compared to diesel generators. With the growth of the green hydrogen sector, Serene fuel cells will accelerate the move towards the generation of net-zero emission electricity through the use of e-methanol as fuel created from green hydrogen.

09:22 EST Zhongchao's MDMOOC Platform to apply ChatGPT technology - Zhongchao announced that its MDMOOC Platform will apply the ChatGPT, or Chat Generative Pre-trained Transformer, to provide assistance for physicians in clinical decision-making to improve the efficiency of diagnosis and treatment. This is an expanded application of ChatGPT by Zhongchao since its initial application of ChatGPT to elevate patient management service capabilities and experience. The application of ChatGPT will be available on the MDMOOC ChatGPT Wechat Public Account, a public account on WeChat. Physicians can utilize MDMOOC ChatGPT to access the latest information on diseases, diagnostic criteria, treatment options, research data, and guidelines. In addition, physicians will be alerted that contents provided by ChatGPT will be solely for reference and convenience to users and shall not be relied on for diagnostic or treatment purposes. The application of ChatGPT will allow physicians to quickly comprehend multidisciplinary knowledge and clinical data as needed in developing comprehensive and up-to-date treatment plans for individual patients.

09:17 EST Atossa Therapeutics granted new patent for endoxifen - Atossa Therapeutics announces that the United States Patent and Trademark Office, USPTO, has granted a new patent directed to (Z)-endoxifen encapsulated in an enteric capsule. This patent further reinforces Atossa's broad Intellectual Property portfolio related to (Z)-endoxifen. A short 'explainer' video about the new patent can be found here: Patent Update - Video Explainer. "We are very pleased with the scope and breadth of this new key patent," said Dr. Steven Quay, Atossa's President and Chief Executive Officer. "It ensures that in the U.S., Atossa will have the only (Z)-endoxifen treatment delivered orally with an enteric capsule, which we believe is the optimal way to deliver the drug. This new patent, further strengthens our intellectual property estate and should create long-term stockholder value." Atossa is developing its proprietary (Z)-endoxifen in both the breast cancer treatment and prevention settings. Phase 2 trials are ongoing with the goal of changing the treatment paradigm for patients who are not benefiting from currently approved drugs and helping reduce the incidence of breast cancer.

09:16 EST PlayAGS appoints Robert Ziems as Chief Legal Officer - PlayAGS announced that Robert "Rob" Ziems will join the Company as Chief Legal Officer, effective immediately. Ziems brings over 24 years of gaming and legal experience to AGS and will lead the Company's legal and compliance affairs and oversee the Latin America and Interactive business strategy. Ziems joins AGS from Aruze Gaming America, where he served for over 12 years. Most recently he served as President of Aruze, Global Chief Legal Officer of Aruze Gaming Group, and Corporate Secretary. At Aruze, Ziems led global legal affairs, regulatory compliance, and global human resources. In addition, he oversaw operating efficiencies, business development, and procurement in the Americas. Ziems has served as in-house counsel for gaming corporations for most of his career handling legal and regulatory matters worldwide. Prior to Aruze, he served as Executive Vice President, General Counsel, and Corporate Secretary of Mikohn Gaming, later known as Progressive Gaming International Corporation, where he managed the global legal, human resources, compliance, and internal audit departments, in addition to overseeing all corporate activities. Ziems succeeds Victor Gallo, who has retired as AGS' General Counsel after serving since 2010. Gallo will remain as Secretary for the Company.

09:16 EST Virpax announces preclinical toxicology results supporting MET - Virpax Pharmaceuticals announced that the Company has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology . MET enhances the delivery of Virpax's non-addictive pain product and its epilepsy product candidate. MET is also utilized in the Company's viral barrier product candidate. These preclinical toxicology studies were performed to evaluate the safety of the MET platform and to support the IND submission of each product candidate. The Molecular Envelope Technology was developed by Nanomerics Ltd., a UK-based nanotechnology research and development company. Nanomerics has licensed its technology to Virpax, which is utilizing the nose-to-brain MET platform to enhance drug delivery for certain of its product candidates. "We are working with a variety of CROs and scientific and pharmaceutical industry leaders to help us evaluate the safety of the MET platform, which underpins a number of our current drug development efforts such as AnQlar which is our viral barrier product candidate. We anticipate that MET will also be a part of our plans for current and future drug development programs. We have engaged Dr. Jeffrey Murray, a leading expert in infectious diseases who spent almost 30 years of his career with the FDA, including as the Deputy Division Director for the Division of Antivirals, Center for Drug Evaluation and Research. Dr. Murray has published many articles related to antivirals and served as a reviewer for the New England Journal of Medicine while at FDA. He has been a valuable contributor to us in the antiviral area in addition to clinical trial design," commented Dr. Sheila A. Mathias, Chief Scientific Officer for Virpax.

09:13 EST Gold Resource sees FY23 payable production 17K- 19K gold ounces - Sees cash costs after by-product credits per gold equivalent or AuEq ounce $1,000 to $1,050.

09:13 EST Forian announces sale of BioTrack to Alleaves for $30M in cash - Forian announced the sale of Forian's cannabis software subsidiary, Bio-Tech Medical Software, to Alleaves, a provider of ERP software solutions to the cannabis industry, effective February 10, 2023, for a total purchase price of $30M in cash, comprised of $20M paid at closing and $10M paid in twelve required equal monthly installments, subject to any working capital adjustments. Forian will retain a license to certain cannabinoid-based data to enhance its healthcare information offerings. As a result of the transaction, Forian will focus on its healthcare information business and will no longer provide software solutions to the cannabis industry. "This transaction allows us to focus our efforts on our healthcare information business, which has been the key driver of our growth to date and will further accelerate our path to positive Adjusted EBITDA," said Max Wygod, Executive Chairman of Forian.

09:11 EST Goal Acquisitions announces extension to consummate Digital Virgo combination - Goal Acquisitions announced that on February 7, 2023 its shareholders approved an extension to extend the period of time to consummate an initial business combination to March 18, 2023, subject to extension by the Board of Directors for up to five additional thirty-day periods. More than 89% of shareholders voted in favor of the extension, 9,546,357 public shares remain outstanding, and Goal expects to have approximately $97,029,243 remaining in the trust account. Upon closing of the business combination, Digital Virgo is expected to be the publicly traded entity for the combined company. Closing is conditioned upon, among other things, regulatory and shareholder approval.

09:09 EST Gold Resource: Lower gold grades to result in less production in 2023 - Gold Resource Corporation remains focused on unlocking the value of our Mexican mine, existing infrastructure, and large property position. Additionally, the Company remains committed to optimizing the mine plan and process flowsheets for the Back Forty Project. With that said, the 2022 market volatility, challenging economic conditions and the lower grade profile of our current Mineral Reserves and Mineral Resources, have collectively contributed to an adverse impact on our 2022 cash flows and consolidated earnings. While we are focused on organic growth and disciplined cost cutting initiatives, the lower grade profile is expected to continue through 2023 and is projected to negatively impact operating cash flows and total cash costs per gold equivalent ounce, as reflected in the guidance table below. Allen Palmiere, President and CEO, said, "2022 was a challenging year for the Company on a number of fronts; however, we made excellent strides with our operations, capital and exploration programs. Further, I remain very proud of how our workforce embraced our objectives and values around safety, operational process improvement and collaboration with our internal and external stakeholders. We will continue identifying operational efficiencies and cost improvement opportunities in 2023; however, as per our 2023 guidance, lower gold grades will result in less production in 2023 than 2022 and further significantly contribute to an increased Cash Costs and All-in Sustaining Costs. More importantly, we are eager to advance the exploration drilling at a number of highly prospective underground targets in Mexico. With the Back Forty Project, we will continue work on the feasibility study with a deliberate and measured approach. I remain optimistic that this year will provide opportunities to grow the Company in new directions."

09:08 EST Inpixon sets record date for distribution of CXApp stock to its securityholders - Inpixon (INPX) announced that its board of directors has set March 6 as the record date for the dividend of shares of common stock of CXApp Holding to be distributed to Inpixon securityholders in order to effect the spin-off of Inpixon's enterprise apps business. The dividend in CXApp Holding shares is expected to be distributed to holders of Inpixon's outstanding capital stock and certain other securities as of the Record Date on or about March 14, the expected closing date of the previously announced business combination between CXApp Holding and KINS Technology Group (KINZ). Following the closing of the Business Combination, KINS will change its name to "CXApp Inc." and begin trading on the Nasdaq Capital Market under the stock ticker symbol "CXAI," and Inpixon will continue to trade on the Nasdaq Capital Market under the stock ticker symbol "INPX." Inpixon Securityholders will receive shares of CXApp Holding common stock on a pro rata basis representing 100% of Inpixon's interest in CXApp Holding. Immediately following the distribution of CXApp Holding shares, the Business Combination is expected to close. Upon the closing of the Business Combination, all shares of CXApp Holding common stock will be automatically exchanged for shares of New CXApp on a pro rata basis according to an exchange ratio calculated immediately prior to closing using a formula set forth in the merger agreement by and among Inpixon, CXApp Holding, KINS and a subsidiary of KINS. Inpixon Securityholders will receive an aggregate of approximately 6,900,000 shares of New CXApp common stock in exchange for their shares of CXApp Holding common stock.

09:07 EST LPL Financial: Legacy Financial Group joins broker-dealer, RIA platforms - LPL Financial announced that Legacy Financial Group has joined LPL Financial's broker-dealer and RIA. The Legacy team reported having served approximately $225 million in advisory, brokerage and retirement plan assets, and joins LPL from Voya Financial Advisors. Legacy Financial Group, based in Albuquerque, NM, originated August of 1995. Cris Giron started his financial planning career cold calling potential clients, primarily educators in an underserved market, helping them save money into 403(b)'s and plan for retirement. Eddie Fernandez was working for a local prominent CPA firm doing traditional accounting services that focused on historical activity but felt he was better at serving clients by focusing on their future planning needs.

09:05 EST G Medical Innovations receives patent from USPTO for vital sign sensors - G Medical Innovations Holdings announced that the patent US 11,571,167 "Method and System For Vital Signs Monitoring With Earpiece" has been issued as of February 7, 2023. Two weeks ago, G Medical Innovations announced it received a patent issue notification from the United States Patent and Trademark Office in connection with this patent, which joins the growing list of the Company's patent portfolio. The patent covers the vital signs monitoring system that the Company is developing using multiple sensing mechanisms to be used on different body locations. This vital sign monitoring system will potentially provide physicians more versatility in patients' monitoring and would simplify in and out-patients' monitoring. Together with the two patents received in December 2022, G Medical Innovations continues to strengthen its position in the market with its unique technologies and services. The Company believes that obtaining these patents places the Company at the forefront of the industry and provides the Company a significant advantage over its competitors, specifically with regards to accurate monitoring of patients. This will potentially allow the Company to increase the market size for its products and its monitoring services.

09:04 EST Fat Brands' Twin Peaks nears 100 locations to finish 2022 - FAT Brands is pleased to announce another strong year for Twin Peaks. The leading sports lodge concept generated strong growth throughout 2022 in addition to landing top spots on several prestigious awards lists. In total, the banner year saw Twin Peaks open nine new lodges, while also signing four new area development agreements to add 26 future lodges in the United States and one ADA in Mexico for an additional 32 lodges. These agreements are expected to allow the brand to surpass the monumental 100-restaurant milestone by spring of 2023. The brand enters 2023 with 95 locations across the United States and Mexico with an anticipated 18-20 additional restaurants opening in 2023 in Chattanooga, Tennessee; Greenwood, Indiana; Deer Valley, Arizona; Columbus, Ohio; Springfield, Missouri; as well as Daytona Beach and Jacksonville, Florida to begin the year. The brand signed several domestic ADAs to expand its footprint, including eight locations across North Carolina with Music City Consulting, four locations in the Ohio River Valley with JEB Food Group and three restaurants in the Pittsburgh area with the Falcons Group. Twin Peaks also secured an agreement with Dos Montes Corp. to add seven locations in Chicago and its largest international ADA to date with its subsidiary, Operadora 2 Montes, for 32 lodges in Mexico.

09:03 EST Precision Optics signs license agreement with global medical device company - Precision Optics announced it has signed a production and technology license agreement with a large, global medical device company. The licensing agreement arises from a joint product development initiative with this customer over the past four years. The agreement grants the medical device company exclusive rights for an agreed period of time to certain POC intellectual property, within a defined and limited field of use in the ophthalmic industry. The agreement sets terms under which POC will manufacture the product or receive royalties if the product is manufactured by the customer or a third-party. Under the agreement, POC has received a one-time upfront payment of $600,000 for these technology rights. Initial production of this product is expected to occur at POC's facilities in late-2023. The customer has the right to transfer production to one of their facilities or to a third-party manufacturer, in which case POC would assist in such transfer and would be paid royalties for a period of time on all product manufactured at a non-POC facility.

09:02 EST Rocket Companies announces retirement of CEO Jay Farner and succession plan - Rocket announced that following a 27-year career at the Company, CEO Jay Farner plans to retire from his position effective June 1. At that time, Bill Emerson, longtime Rocket executive and current Vice Chairman of Rock Holdings, will assume the role of CEO on an interim basis. Farner will begin transitioning his roles and responsibilities to Emerson to ensure a seamless transition on June 1. Farner has also decided to step down from his position on the Rocket Board of Directors, effective February 9, 2023, and Emerson has been appointed to the Board, effective immediately. The Board of Directors has commenced a search for a permanent CEO and has retained a leading firm to support its evaluation of internal and external candidates.

08:57 EST Hyperfine announces FDA clearance for upgraded AI-powered softwae - Hyperfine announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the company's upgraded AI-powered software. The most recently cleared Swoop software improves the image quality of the diffusion-weighting imaging sequence with increases in its signal-to-noise ratio. An additional update in this software release increases the Swoop Portable MR Imaging System field of view by 10% for T1, T2, and FLAIR sequences to match the previously improved DWI sequence's 20cm field of view. Field of view size is important for visualizing pathology deep in the brain.

08:49 EST Aemetis unveils five-year plan targeting $2B of revenue in 2027 - Aemetis released an updated Five Year Plan that provides insights into the Company's plans to generate $2B of Revenues, $496M of Net Income, and $682M Adjusted EBITDA in year 2027. The Five Year Plan reflects a projected Revenues compound annual growth rate of 43% and a projected Adjusted EBITDA compound annual growth rate of 77% between 2023 and 2027. A presentation describing the Five Year Plan was filed with the SEC and is posted on the Aemetis website. The Plan includes the expansion of the company by the production of negative carbon intensity Renewable Natural Gas; Sustainable Aviation Fuel; Renewable Diesel fuel; carbon sequestration of CO 2 ; and other low- and below-zero-carbon products produced from the Aemetis' ecosystem of renewable projects. The presentation profiles the capital expenditures for the projects, as well as the positive financial impact of the Inflation Reduction Act.Under the Five Year Plan, the Company plans revenue growth in all of our product lines, including: expansion of pipeline and digester construction within our dairy RNG business; construction of the 90 million gallon per year Aemetis renewable jet/diesel plant; drilling two CO 2 Carbon Sequestration and Underground Storage characterization and injection wells installed near the California biofuels plant sites; improving energy efficiencies and electrification projects at our Keyes biofuels plant; and expected changes to India government policies that allow the India plant to operate closer to its full capacity due to a new tax on unblended diesel starting in April 2023. The provisions of the Inflation Reduction Act provide for the transfer of tax credits from incentives connected to the production of product, as well as investment tax credits and other credits. In total, these tax credits improve Net Income by a projected $341M in year 2027. The plan for the Aemetis Dairy RNG business shows revenues growing from $2M in 2023 to $302M in 2027, with Adjusted EBITDA is expected to expand from $29.2M in 2023 to $264.1M in 2027. The plan includes the delays related to the regulatory process to obtain LCFS credit pathway approvals for each dairy digester. Aemetis has been awarded $23M of grants related to dairy RNG and related gas cleanup and utility pipeline interconnection units, including a $1M grant to install an RNG dispensing station to fuel RNG trucks at the Keyes plant. The projected $302less than of dairy RNG revenues in year 2027 is sourced from the construction and operation of digesters representing 127,942 wet cow equivalents and generating 1.5M MMBtu's at Aemetis at an estimated -400 carbon intensity RNG. The projected Aemetis Carbon Zero SAF/RD revenues of $701M with $192M of Adjusted EBITDA in 2027 is expected to be generated from the 90M gallon per year plant being developed at the 125-acre Riverbank Industrial Complex. The Riverbank SAF/RD plant is designed to utilize the Riverbank site's access to 100% renewable hydroelectricity; a rail line with storage for 120 railcars; 710,000 square feet of buildings; and 50 acres of open land that already has received key environmental and zoning approvals. Based on the completion of carbon reduction upgrades at the Keyes plant, which is expected by 2024, expansions of the India biodiesel plant, and expansion in our market opportunities resulting from changes to governmental policies, the Company expects to generate annual revenue from ethanol and biodiesel of approximately $700M by 2027, up from approximately $340M of expected revenue in 2023, an increase of 106%. The Keyes ethanol plant upgrades include the Mitsubishi ZEBREX ceramic membrane ethanol/water separation unit and MVR utilizing electric turbo fans to reduce natural gas use powered with zero-carbon intensity solar microgrid with battery storage.

08:44 EST Check Point: Cyberattacks growing, becoming more sophisticated

08:43 EST Reliance Global expands platform with new CRM tools - Reliance Global Group announced that it has significantly enhanced its AI-based, InsurTech platform with new customer relationship management, CRM, tools to further enhance workflow, streamline operations, and reduce costs for insurance agency partners utilizing RELI Exchange. Ezra Beyman, CEO of Reliance Global Group, stated, "We are excited to integrate our advanced AI engine and custom CRM system into our RELI Exchange InsurTech platform. This upgrade follows the recent launch of our real-time, life insurance quotation tool, which compares life insurance policies from over 15 insurance carriers, and builds upon our successful home and auto insurance offerings. We have always been at the forefront of AI-based technologies and, with this integration, we are further elevating our position as an InsurTech leader."

08:41 EST Bright Green receives first funds from EB-5 Program - Bright Green Corporation has received funds from its first applications following the recent announcement of its plans to raise $500 million under the United States Citizenship and Immigration Services' EB-5 Program, an innovative vehicle for spurring investment and job creation in rural communities. USCIS administers the EB-5 Program, under which investors, their spouses and unmarried children under 21 years of age are eligible to apply for a Green Card if they make the necessary investment in a commercial enterprise in the U.S. Bright Green has already started to build its pipeline of potential investors, comprising both individual applicants, as well as large international companies with a global workforce. Receipt of funds from its first applications validates the proof of concept for the EB-5 Program. Bright Green plans to immediately utilize funds generated by the EB-5 Program for working capital requirements to operate its current greenhouse facilities in Grants, New Mexico. The Company also confirms that they are finalizing the State and Federal occupancy requirements. Once fully compliant, the U.S. Drug Enforcement Administration can confirm the registration of Bright Green's license, which will allow the Company to commence planting, harvesting and extraction of its first product.

08:39 EST TOP Ships announces new time charter employment contract - TOP Ships announced that it has entered into a time charter employment contract with a high-quality counterparty for its product/chemical tanker M/T Eco Marina Del Rey. The new time charter will commence immediately after the expiry of the present time charter employment contract in the 1st quarter of 2024 and will have a firm duration of 3 years with an additional year at the charterer's option. The revenue backlog expected to be generated by this fixture is about $22.4M for the firm period and about $30.6M if the charterer exercises the option to extend for one additional year. Evangelos Pistiolis, the President, Chief Executive Officer and Director of the Company, said: "We are very happy to have concluded this new fixture of M/T Eco Marina Del Rey more than a year ahead of the expiry of its present employment and at a daily rate which is about 36% higher than the current rate, thereby taking advantage of the strong rates prevailing in the current tanker market. After considering this fixture, the total gross revenue backlog for the firm time charter period of our operating vessels, as of December 31, 2022, stands at about $259 million, increasing to about $280 million when adding the 50% of our joint venture vessels.

08:38 EST Sypris wins award for long-range standoff missile system assemblies, no terms - Sypris Electronics announced that it has recently received an award to produce and test electronic interface control assemblies for the U.S. Department of Defense Long-Range Standoff missile weapons system as part of the Nuclear Weapons Delivery Systems modernization program. Production is expected to begin in 2023. Terms of the agreement were not disclosed. The assemblies to be produced by Sypris will be incorporated into the suite of strategic nuclear and tactical weapons systems of the U.S. Air Force B-52H long-range bomber. The LRSO weapon system is targeted to replace the nearly 40-year old AGM-86B Air-Launched Cruise Missile. According to news sources, the LRSO weapon system is being developed as a program that can penetrate and survive integrated air defense systems and attack strategic threats.

08:37 EST Safe & Green obtains certificate of occupancy for Monticello project - Safe & Green announced that the company has obtained a certificate of occupancy for its Monticello project, located in the Catskills region. Given that the property has now been deemed habitable and meets all code and usage requirements, the leasing process can begin.

08:36 EST Everbridge appoints John Di Leo Chief Revenue Officer - Everbridge announced the appointment of John Di Leo as Chief Revenue Officer, responsible for leading the company's global sales and go-to-market teams including global partnerships, business development, professional services, and Everbridge's centers of excellence. Mr. Di Leo joins Everbridge, effective immediately, and reports to Chief Executive Officer David Wagner.

08:36 EST Silo Pharma files patent for treatment of Alzheimer's disease - Silo Pharma announced that it has filed a provisional patent application for the use of its central nervous system homing peptides to treat Alzheimer's disease and the onset of dementia. Alzheimer's disease has proven to be a progressive neurodegenerative disorder that is associated with the destruction of higher brain structures, such as those involved in cognition and memory function. The disease leads to deficits and declines in memory, learning, language, and in the ability to perform intentional and purposeful movements. Alzheimer's disease is also accompanied by concomitant behavioral, emotional, interpersonal, and social deterioration. Treatment of Alzheimer's remains largely inadequate. Silo Pharma continues to explore the use of its CNS homing peptides along with its study of other novel therapeutics currently in preclinical studies.

08:34 EST Acer Therapeutics announces full enrollment in Phase 2a trial of ACER-801 - Acer Therapeutics announced full enrollment of its Phase 2a proof of concept trial of ACER-801, a novel, non-hormonal, neurokinin 3 receptor antagonist, being investigated as a potential treatment option for moderate to severe Vasomotor Symptoms, VMS, associated with menopause. Topline results from this trial are expected in mid-March 2023. The Phase 2a randomized, double-blind, placebo-controlled, dose-ranging trial of ACER-801 is designed to evaluate the safety, pharmacokinetics and efficacy of ACER-801 in 48 postmenopausal women aged 40-65 who experience moderate to severe hot flashes. Subjects were randomized 1:1:1:1 and receive twice daily doses of either 50mg, 100mg, 200mg of ACER-801 or placebo over a 14-day treatment period, followed by a 14-day safety follow-up assessment. Results from this trial could provide proof of concept data in postmenopausal women and could inform ACER-801 dosing and a development path forward in patients with induced Vasomotor Symptoms.

08:31 EST Zenvia launches integration of ChatGPT to its mass texting service solution - Zenvia launched the integration of its mass texting service solution, Zenvia Attraction, with ChatGPT via API. Zenvia Attraction, a SaaS tool that leverages the relationship of companies with their customers, can now provide increasingly personalized and efficient suggestions in the elaboration of messages.

08:25 EST Aptevo, Alligator dose first patient in Phase 1 trial of ALG.APV-527 - Alligator Bioscience and Aptevo Therapeutics announced the dosing of the first patient in the companies' Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors expressing the tumor-associated antigen 5T4. ALG.APV-527 is a bispecific antibody with a tumor-directed 4-1BB agonistic effect and the ability to specifically stimulate antitumor-specific T cells and NK cells involved in tumor control. The ALG.APV-527 Phase 1 trial is a multi-center, multi-cohort, open-label trial that will include six cohorts in a 3+3 design. The trial will be conducted at up to 10 sites in the U.S. among adult patients with multiple solid tumor types/histologies likely to express the 5T4 antigen, including non-small cell lung cancer (NSCLC), gastric/gastro-esophageal cancer and head and neck cancer. ALG.APV-527 will be given intravenously once every two weeks. The trial will assess the safety and tolerability, pharmacokinetic, pharmacodynamic and preliminary anti-tumor activity of ALG.APV-527.

08:21 EST Frequency announces FX-332 study misses endpoint, to reduce personnel by 55% - Frequency Therapeutics announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss, or SNHL. The study, which enrolled 142 people with either sudden or noise-induced sensorineural hearing loss, failed to achieve its primary efficacy endpoint of an improvement in speech perception. Data showed no statistically meaningful difference at day 90 between those administered FX-322 versus those receiving placebo in the proportion of individuals that demonstrated an improvement in speech perception. There were also no measurable improvements observed in any of the study's secondary endpoints. Prior FX-322 studies had been designed to best understand patient etiologies and severities where a hearing signal could be observed. FX-322-208 was statistically powered with a balanced placebo and active group. The safety profile associated with FX-322 was favorable and no study participants experienced a serious adverse event that was associated with treatment. The company will now discontinue the FX-322 development program. In addition, while dosing of FX-345, a second program to treat SNHL, has been completed in the initial safety cohort of an ongoing Phase 1b trial, that development program will also be discontinued. The company will now focus its resources to advance its remyelination in MS program into the clinic. Frequency's efforts now will focus on continuing to develop novel therapeutics to induce remyelination for individuals living with MS. The Company previously reported that it had identified a novel target relevant to myelination. Modulation of this target drives robust oligodendrocyte differentiation and expression of myelin proteins in vitro. The Company has identified multiple novel chemical entities that induce robust remyelination following demyelination in an adult in vivo animal model. The MS program is independent of the hearing program, with a distinct molecular target, mechanism, progenitor cell population, and small molecule drug candidates. Further, a well-defined clinical path with objective biomarkers such as visual evoked potential, or VEP, and magnetic resonance imaging exist for studying the performance of remyelination therapies in MS patients. Frequency's agents substantially outperform other clinically studied remyelination agents in head-to-head in vivo studies. Frequency plans to begin its clinical program for remyelination in 1H 2024. The company will immediately reduce headcount as part of an overall restructuring, downsizing personnel by approximately 55% . The company believes that the restructuring will generate sufficient cost savings to extend its runway into 2025 and enable it to complete a first clinical trial of its MS program in 2H 2024. As of December 31, 2022, Frequency had cash, cash equivalents and marketable securities of $83.1M.

08:17 EST MSG Sports to invest up to C$13.4M in Xtract One - Xtract One Technologies (XTRAF), and Madison Square Garden Sports Corp. (MSGS) announced that MSG Sports will invest up to C$13.4M in Xtract One. The initial investment of C$8.4M is effective immediately, with the subsequent investment of C$5M being conditional on the approval of Xtract One's shareholders and all applicable regulatory approvals. The Investment is comprised of the sale of up to 31,925,595 units at a price of C$0.42 per Unit. Each Unit will be comprised of one common share of Xtract One and one Common Share purchase warrant exercisable at a price of C$0.60 for a period of five years following the date of its issuance. The initial tranche of the Investment comprised the issuance of 20,000,000 Units for aggregate gross proceeds of C$8,400,000. The proposed second tranche of the Investment will be comprised of the issuance of 11,925,595 Units for aggregate gross proceeds of C$5,008,749.90. All securities issued under the Investment will be subject to Canadian resale restrictions of four months and one day, in addition to applicable US resale restrictions. No commission or fee is or will be paid in connection with the Investment. The initial and proposed subsequent equity Investment will enable Xtract One to further innovate its advanced security solution and accelerate its growth into new market segments. The investment by MSG Sports took place through its wholly-owned subsidiary MSG Sports Ventures, which is located at 2 Penn Plaza, New York, New York 10121. Prior to its investment, MSGSV did not hold any securities of Xtract One. As a result of its investment for total gross proceeds of C$8.4M, MSGSV holds 20,000,000 Common Shares and 20,000,000 Warrants, representing approximately 10.92% of the issued and outstanding Common Shares on a non-diluted basis and 19.69% on a partially diluted basis. Should its investment increase to C$13.4M, MSGSV would hold an aggregate of 31,925,595 Common Shares and 31,925,595 Warrants, representing approximately 16.36% of the issued and outstanding Common Shares on a non-diluted basis, and 28.12% of the issued and outstanding Common Shares on a partially diluted basis, based on the current issued and outstanding Common Shares. In connection with its investment, MSGSV entered into an investor rights agreement with Xtract One pursuant to the terms of which MSGSV has been granted the right to appoint an observer to the board of directors of Xtract One. Under the Investor Rights Agreement, subject to certain limitations set forth therein, MSGSV is also entitled to: certain "demand" registration rights that will allow MSGSV to request that Xtract One qualify for resale under Canadian securities laws and/or register for resale under the United States Securities Act of 1933, as amended, any Common Shares acquired by MSGSV as a result of its investment or upon exercise of the Warrants; and certain "piggyback" registration rights that will allow MSGSV to include the Registrable Securities in any public offering of equity securities initiated by Xtract One or another shareholder having registration rights.

08:16 EST BIO-key partners with Europe's Bravantic Group - BIO-key International announced a strategic distribution partnership with Bravantic Group to bring its solutions to customers in Southern Europe, Africa, Brazil and the Middle East. Bravantic Group has a strong presence in Portugal, the United Kingdom, Angola, Mozambique, Cape Verde, Brazil, Abu Dhabi, and Dubai. Over the last 26 years they have worked with major hardware and software manufacturers to offer a wide range of information technology and security solutions and services across a variety of industries and enterprises. BIO-key continues to expand its footprint in high growth international markets by offering its leading identity solutions through key strategic partners like Bravantic.

08:13 EST Victoria Gold provides notice of expiry of offer for ATAC Resources - Victoria Gold is providing notice that its proposed offer to ATAC Resources will expire at the close of business on February 17, 2023. On January 12, 2023, Victoria submitted a non-binding proposal to acquire 100% of the issued share capital of ATAC. Victoria proposed to offer C$0.12 per ATAC share, payable in Victoria shares. On January 17, 2023, ATAC declined Victoria's proposal. Following subsequent discussions between ATAC and Victoria and their respective advisors, ATAC formally confirmed its rejection of Victoria's proposal on February 7, 2023. Victoria believes its offer is fair and generous consideration for ATAC shareholders. Victoria's offer implies a premium of 85 percent to ATAC's closing share price on February 10, 2023. To provide ATAC's Board of Directors time to reconsider its prior rejection of Victoria's offer, Victoria is extending its offer until 5:00pm on Friday, February 17, 2023. Following this, Victoria's proposal to acquire ATAC will expire. Victoria has no intention of commencing a hostile take-over offer.

08:11 EST HomeTrust completes merger with Quantum Capital - HomeTrust Bancshares, the holding company of HomeTrust Bank, announced that its merger with Quantum Capital was completed as of February 12, 2023. The merger was a stock and cash transaction valued at approximately $70.8M. On a pro forma basis, the combined entity will hold assets of approximately $4.3B, including loans of $3.6B and deposits of $3.6B. "We are pleased to announce the completion of our merger with Quantum and can now officially welcome this talented group of bankers to the HomeTrust team," said C. Hunter Westbrook, President and Chief Executive Officer of HomeTrust. "Very early in the process we realized Quantum had a culture similar to ours that is employee first while being deeply committed to enriching our customers and communities, and this belief has only been strengthened over time. We look forward to demonstrating what we can achieve together." After closing the Transaction, Bryan Cohen, the former President of Quantum and Chief Executive Officer of Quantum National Bank, will serve as the Georgia Market President of HomeTrust Bank, while Dr. Narasimhulu Neelagaru will join the boards of directors of HomeTrust and HomeTrust Bank in June 2023. As a result of the merger, HomeTrust is paying approximately $33.0M of cash and issuing 1,374,646 shares of HomeTrust common stock to the shareholders of Quantum. Also, as part of the Transaction, Quantum's subsidiary, Quantum National Bank, has merged with and into HomeTrust's subsidiary, HomeTrust Bank. HomeTrust will continue to operate Quantum National Bank's branch offices under the Quantum National Bank name until the systems conversion scheduled for mid-March 2023.

08:11 EST AnPac Bio signs agreement to acquire a group of Windfall affiliated companies - AnPac Bio-Medical Science announced that on February 12 the Company, through its subsidiary Foodbase Group entered into a definitive equity purchase agreement to acquire a group of affiliated companies, SLV Windfall Group, Windfall SLV Development and SLV Windfall Management, which are engaged in developing, marketing and selling real estate in Savannah Lakes Village, a planned community located in McCormick County, South Carolina. SLV Windfall Group currently owns a few dozens of buildable lots, approximately 500 acres of undeveloped land for future development projects, and has secured the exclusive right to purchase on favorable terms from the local land authorities over 2,000 buildable lot. Savannah Lakes Village is a well-developed community which has been in existence for more than 30 years. The Company plans to file the necessary applications to qualify the land development at Savannah Lakes Village as a U.S. EB-5 immigration investment project. Pursuant to the equity purchase agreement, the Company agreed to purchase 100% of the issued and outstanding equity interests of the affiliated companies for an aggregate consideration of $28,000,000, payable in the form of cash in four installment payments pursuant to a payment schedule based on milestone events. The initial closing of the transaction is expected to take place in the in the Q2.

08:10 EST Enphase Energy, Lumio expand solar technology across U.S. - Enphase Energy announced that Lumio, a leader in personalized renewable energy, will significantly expand its offering of Enphase IQ8 Microinverters and IQ Batteries to customers across the United States. "We're proud to continue our work with Lumio to leverage its leadership in delivering customizable, reliable, and safer clean-energy solutions to homeowners nationwide," said Dave Ranhoff, chief commercial officer at Enphase Energy. "Our combined focus on high-quality home energy solutions and excellent customer service will offer homeowners a world-class experience end-to-end."

08:09 EST Seelos Therapeutics completes enrollment in Phase II/III trial of SLS-005 - Seelos Therapeutics announced the completion of enrollment of its registrational Phase II/III trial studying the investigational treatment SLS-005 for the treatment of amyotrophic lateral sclerosis on the HEALEY ALS Platform Trial. Seelos plans to initiate an Expanded Access Program late in the first quarter of this year that is fully funded by a grant from the NINDS under the ACT for ALS. Under this EAP, Seelos plans to enroll 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS who do not qualify for other ongoing clinical trials, thus offering these patients an experimental treatment that they may not otherwise have access to.

08:08 EST Akari Therapeutics announces acceleration of Phase 3 trial of nomacopan - Akari Therapeutics announced the Phase 3 clinical trial of nomacopan in pediatric patients with hematopoietic stem cell transplant-related thrombotic microangiopathy, HSCT-TMA, is moving into Part B sooner than expected and the company is beginning the planning and design for the pivotal study in pediatric patients over 2 years of age. Akari also announces it has added a new pipeline program that will develop nomacopan as a potential treatment for adult HSCT-TMA, which will include a study that is supportive of the pediatric program. Study enrollment for the adult program is expected in 2024. Part A of the Phase 3 clinical trial of nomacopan in pediatric HSCT-TMA was designed to include three cohorts. Akari enrolled patients in the two older age groups and, based on feedback from the FDA, the PK/PD data from these patients from the Part A study are consistent with the predictions derived from Akari's latest PK/PD model. Since enrollment for the youngest age cohort in the Part A pediatric study is not completed Akari is keeping the study open for this youngest group of pediatric patients while advancing the pivotal Part B study of nomacopan in the older pediatric patients. Akari participated in the FDA Model-Informed Drug Development program to refine the Akari PK/PD model suitability and doses for the Phase 3 clinical trial of nomacopan in pediatric HSCT-TMA. Clinical data from 38 subjects were included in the Akari PK/PD model, which was used to predict dosing for pediatric HSCT-TMA patients through 10,000 virtual patient simulations. These informed FDA MIDD interactions that confirmed PK/PD model suitability and doses selected for the nomacopan Phase 3 Part A clinical trial in pediatric HSCT-TMA. An expanded PK/PD model using data from 55 patients treated with nomacopan was reviewed in the recent Type C interaction with the FDA along with PK/PD data from the Part A study. "We made the important decision to not wait for Part A to be completed before we reached out to the FDA for Type C feedback on our next steps toward the pivotal study, an interaction which we had originally estimated would be mid-year 2023. This earlier feedback enabled the acceleration into the Part B clinical trial of nomacopan in pediatric HSCT-TMA," said Rachelle Jacques, President and CEO of Akari. "Our decision to initiate a new pipeline program to develop nomacopan as a potential treatment for adults with HSCT-TMA was also an important one and will support our pediatric program. The significant unmet need is shared among both children and adults with dismal outcomes and no approved treatment options."

08:07 EST SmileDirectClub launches CarePlus premium aligner offering - SmileDirectClub announced the launch of its new premium aligner treatment, CarePlus. Available now at select Partner Network dentist locations, CarePlus delivers a higher touch, tech-forward option in orthodontic care with greater flexibility and choice through a combination of both in-person and virtual patient management, value added services, and concierge-level care from SmileDirectClub's network of licensed dentists, orthodontists, hygienists, and dental assistants. To get started, CarePlus customers visit a participating Partner Network dental office for a 3D scan and dentist consultation to begin their clear aligner treatment, whether it's the Company's 22-hour regular-wear aligners or nighttime-only 10-hour program. Customers can pay the $3900 cost in full or choose the less than $115 monthly extended payment plan with the SmileDirectClub's FlexPay option.

08:05 EST Jack Henry raises quarterly dividend 7% to 52c per share - The cash dividend on its common stock is payable on March 24 to stockholders of record as of March 8.

08:05 EST Univar Solutions, Kalsec enter exclusive distribution agreement - Univar Solutions Colombia, SAS, a subsidiary of Univar Solutions, and Kalsec have entered into an exclusive distribution agreement for Kalsec's full food ingredients product range in Colombia. Univar Solutions customers in Colombia now have access to a broader range of ingredient innovations focused on taste and sensory solutions, natural colors and coloring foodstuffs, and food protection business units.

08:04 EST Nuvei, Mercedes-AMG PETRONAS Formula One Team enter partnership - Nuvei Corporation and the Mercedes-AMG PETRONAS Formula One Team announce a multi-year sponsorship agreement that will commence ahead of the 2023 F1 season. From the 2023 Formula One season onwards, the Nuvei logo will appear on the helmet and overalls of the Mercedes-AMG PETRONAS Formula One Team drivers as well as pit crew overalls and team clothing. Nuvei will also be able to utilise team members, including drivers Lewis Hamilton and George Russell, and Team Principal and CEO Toto Wolff for its wider marketing activities for customers, clients, and beyond. Nuvei branding will be unveiled at the Team's 2023 F1 car launch later this week.

08:02 EST Corcept Therapeutics to pay $14M in settlement of class action litigation - Corcept Therapeutics announced that it has reached a preliminary settlement of all claims in the purported securities class action against Corcept and certain of its executive officers captioned Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK, which was pending in the United States District Court for the Northern District of California. Under the proposed settlement, Corcept has agreed to make a one-time payment of $14M, which will be covered in full by Corcept's insurers.

07:41 EST Papa John's unveils new product, Crispy Parm Pizza - Papa Johns announces the all-new Papa Johns Crispy Parm Pizza, a pizza with cheese underneath the crust. Papa Johns Crispy Parm Pizza features our thin crust seasoned with a blend of shredded parmesan-Romano cheeses and can be ordered with the customer's toppings of choice. "At Papa Johns, we pride ourselves on our dedication to innovation. For this product, we set our sights on one of the most fundamental pizza ingredients-cheese," said Kimberly Bean, VP of Menu Strategy & Calendar Planning. "We have taken cheese where we've never had it before-flipping the pizza over and putting it underneath the crust. In doing so, we are providing consumers with more ability to customize their pizza experience, while also enjoying a unique and surprising twist on a fan-favourite meal."

07:38 EST Magna wins battery enclosures business from General Motors - Magna (MGA) announced that it has secured new business from General Motors (GM) to supply battery enclosures on the all-new 2024 Chevrolet Silverado EV. The company will produce the enclosures at its Magna Electric Vehicle Structures facility in St. Clair, Michigan, where it already produces the battery enclosure for the GMC HUMMER EV. Magna recently announced significant investment plans for the facility in St. Clair to support the fast-growing electric vehicle market. Production is expected to begin later in 2023. "The accelerating shift toward vehicle electrification opens up exciting growth opportunities for Magna beyond powertrain," said John O'Hara, President of Magna's body and chassis group. "We have been able to leverage our expertise to supply battery enclosures - a product for which we see strong potential going forward. We have our eye on the future and are proud to play such a critical role in GM's next generation of electric trucks."

07:36 EST San Cristbal Mining completes acquisition of Minera San Cristobal - San Cristobal Mining announced that it has completed the acquisition of Minera San Cristobal S.A. and all of its associated assets from Sumitomo Corporation under the terms of a stock purchase agreement pursuant to which the Company acquired all the issued and outstanding shares of Comercial Metales Blancos AB, SC Minerals Bolivia S.R.L., former subsidiaries of Sumitomo which hold all of the equity interests in MSC. Acquisition Highlights: Acquisition of a globally significant mine; Silver-lead-zinc open pit sulphide mine, with a healthy approximate 7-year mine life; Oxide silver development project with potential to extend operational life through 2040; Exceptional exploration opportunities with potential to add considerable mineral resources. San Cristobal Mining plans to maintain and enhance the strong ESG programs currently in place at MSC, including continued membership within International Council on Mining and Metals. The Company is maintaining the current operational and management team in place at MSC to ensure a smooth transition of ownership To facilitate funding for the Transaction and working capital, San Cristobal Mining entered into funding agreements with Ocean Partners UK Limited and Trafigura Pte Ltd., and completed a non-brokered private placement.

07:34 EST Brainsway CEO Jako to pursue other opportunities, Levy to succeed - BrainsWay announced the appointment of Hadar Levy, the Company's Senior Vice President, SVP, and Chief Operating Officer, COO, and a member of BrainsWay's senior leadership team since 2014, as Chief Executive Officer, CEO. "Levy has been instrumental as a sales, financial and operational leader for the Company throughout his tenure at BrainsWay, previously serving as the Company's Chief Financial Officer and then General Manager North America, before assuming his role as SVP and COO," the company said. Levy succeeds Christopher von Jako, Ph.D., who has decided to step down from the Company to pursue other opportunities.

07:33 EST Ironwood granted priority review for Linzess sNDA from FDA - Ironwood announced that the FDA has granted priority review to the supplemental new drug application, or sNDA, for Linzess for the treatment of children and adolescents ages 6-17 years-old with functional constipation, or FC. The FDA has assigned the application a Prescription Drug User Fee Act or PDUFA, date of June 14th, four months earlier than the standard review cycle.

07:21 EST Appfire announces partnership with Monday.com - Appfire announces a partnership with monday.com, a work operating system where organizations of any size can create the tools and processes they need to manage every aspect of their work, to expand the monday.com app marketplace. This partnership will enable monday.com customers to find apps that fit the unique needs of their business workflows, processes, and projects - all in one place. With Appfire's track record of easy-to-use, powerful, and reliable apps for the world's most reputable tech companies, including, Atlassian, Microsoft Azure DevOps, Salesforce, Microsoft Teams and Slack, joining the monday.com marketplace ecosystem exemplifies Appfire's ongoing commitment to connect every team so they can plan and deliver their best work. To kick off the partnership, Appfire is planning multiple apps to optimize monday.com users' workflow and enable monday.com customers to address a wider set of use cases. The first apps to be released in the coming months will be Planning Poker and Dashboard Hub.

07:20 EST First Wave BioPharma issues letter to stockholders - First Wave BioPharma announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Company's clinical programs and recent events. "We look forward to 2023 after a challenging 2022 when small biotechnology companies endured one of their worst years on record. First Wave BioPharma was not immune to this unfortunate trend, but we weathered the storm. We look forward to capitalizing on several growth drivers in 2023 and reaching our next clinical milestone... Key to our value proposition is the advancement of our adrulipase program. We are excited to have initiated our Phase 2 clinical trial investigating a new enteric microgranule formulation of adrulipase as a potential treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. Patients are now being screened at three clinical trial sites with dosing expected to begin by mid-February. This timeline should enable us to announce topline results sometime in mid-2023... The Phase 2 multi-center study is designed to investigate the safety, tolerability and efficacy of our enhanced formulation of adrulipase in a titrated dose-escalation study involving an estimated twelve patients. The primary efficacy endpoint is the coefficient of fat absorption, with secondary endpoints of stool weight, signs and symptoms of malabsorption, and coefficient of nitrogen absorption... We are eager to test our new formulation of adrulipase in the Phase 2 clinical trial in what we hope is a springboard to advancing adrulipase through a pivotal Phase 3 clinical trial, towards a Biologics License Application, and then potential future commercialization. Our ultimate goal is to provide those suffering from EPI with a therapeutic option that better addresses the numerous, debilitating symptoms they experience on a daily basis and improves their nutritional health and quality of life. If successful, we believe adrulipase has the potential to supplant porcine PERT as the standard of care for EPI associated with CF and CP in an estimated $2.2 billion global market. We recently filed a U.S. Provisional Patent application involving the composition of matter improvements designed to enhance adrulipase's delayed release profile... Our IP protection extends into the 2042-2043 timeframe....In parallel with the clinical, regulatory and IP activities for adrulipase, First Wave has now completed a lengthy, multi-step process to maintain our listing on the Nasdaq Capital Market... Focused on Completion of Adrulipase Phase 2 Trial in 2023. In closing, the past twelve months have been a difficult time for us and biotechnology stocks of all sizes. We have survived those challenges. The Company has significantly reduced its operational spend and headcount and is focused on the successful completion of our Phase 2 trial, a potential value-building event.

07:16 EST Kinross: Mineral resource of 2.7 Moz. indicated, 2.3 inferred for Great Bear - Kinross Gold announce an initial mineral resource estimate for its 100% owned Great Bear project located in Ontario, Canada. The initial mineral resource estimate consists of 2.737 Moz. of indicated resources and 2.290 Moz. of inferred resources. Additionally, the majority of the resource is contained in a high-grade core illustrated in the table below, which is a subset of the resource with cut-off grades increased to 0.9 g/t in the open pit and 3.5 g/t in the underground. Kinross plans to target this higher-grade mineralization in the early years of potential production. Kinross' focus for 2022 was drilling the first ~500 metres at the LP Fault zone to increase confidence in the upper portion of the deposit and facilitate the delivery of the initial mineral resource. The Company drilled over 250 kilometres in 2022, including 225 kilometres of diamond exploration drilling. Combined with the drilling completed by Great Bear since 2018, a total of over 550 kilometres of drilling has now been completed on the property. The results continue to support Kinross' view that the LP Fault zone is expected to host a long-life, high-grade, open-pit and underground mine. Kinross completed comprehensive data analysis to build high quality lithology, alteration, and structural models which feed the Company's mineral resource estimation domains. Kinross also completed a 35-kilometre confirmatory grade control program on a tighter spaced 8 by 10 metre grid with larger diameter holes as compared to the exploration drilling. This program, which covers approximately 1.5 million tonnes of the open pit resource, was used to verify the Great Bear resource model, providing a high level of confidence in our stated resource, which is important given the high amount of visible gold in the deposit.

07:14 EST Aprea Therapeutics announces one-for-twenty reverse stock split - Aprea Therapeutics announced a one-for-twenty reverse stock split of the Company's common stock, par value $0.001, which became effective at 5:00 pm Eastern Time on February 10, 2023. The Company's common stock will trade on the Nasdaq Global Select Market on a split-adjusted basis beginning on February 13, 2023, under the Company's existing trading symbol "APRE". The Company is implementing the reverse stock split as planned to increase the per share price of its common stock to regain compliance with the listing requirements of the Nasdaq Global Select Market. The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 53,631,405 to approximately 2,681,570. There will be no change to the number of authorized shares or the par value per share. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage ownership interest in the Company, except to the extent that the reverse stock split results in any of the Company's stockholders owning a fractional share.

07:12 EST Johnson Controls, PURO UV, Ushio announce research collaboration - Johnson Controls (JCI), PURO Lighting, a subsidiary of Applied UV, (AUVI), and Ushio America, have announced a research collaboration to study the efficacy and safety of filtered far UV-C disinfection technology. The research agreement, which includes technologies and products from PURO and Ushio, will focus on the testing of regulatory-approved filtered far UV-C lighting technologies. The research will be initiated by leading U.S.-based universities and certified laboratories over the next 3-6 months. Because of the importance of this research to public health and well-being, the results will be made publicly available and shared broadly to inform customer choices and public policy.

07:09 EST Clene reports new data from VISIONARY-MS Phase 2 study - Clene and its wholly owned subsidiary Clene Nanomedicine, a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, announced updated MRI results from the Phase 2 double-blinded, 48-week treatment period of the VISIONARY-MS trial in multiple sclerosis, MS, patients. These exploratory MRI results support the previously reported statistically significant clinical improvements in low contrast vision and global neurological function in stable relapsing MS patients reported in the mITT population. VISIONARY-MS investigated the efficacy and safety of CNM-Au8 versus placebo over 48 weeks in stable relapsing remitting MS participants with chronic optic neuropathy. Due to limited enrollment because of the COVID pandemic, the threshold for significance was pre-specified at p=0.10 prior to database lock and submitted to the FDA in the statistical analysis plan. The study was designed to investigate the hypothesis that supporting neuronal energy metabolism protects neurologic function in patients with MS. The MRI findings provide evidence of brain neuronal structural integrity assessed by diffusion tensor imaging that demonstrated statistically significant results for key metrics of axonal integrity and white matter integrity, independent of an immunomodulatory effect. Results include all participants with advanced MRI data collection. Robert Glanzman, MD, FAAN, Clene's Chief Medical Officer, said, "Importantly, these data further reinforce our hypothesis that improving brain energetic metabolism results in improved neurological structure and function when CNM-Au8 is administered as adjunct to standard immunomodulatory disease-modifying MS therapies. Clene plans to initiate a fully powered Phase 3 study to demonstrate improved global neurological function in patients with progression independent of relapse activity, the most urgent unmet need in MS today, in collaboration with a development partner. We look forward to presenting these MRI data at the upcoming forum for Americas Committee for Treatment and Research in Multiple Sclerosis taking place February 22-25, 2023."

07:08 EST Borr Drilling awarded new contract, two extensions for jack-up drilling rigs - Borr Drilling announced it has been awarded a new contract and two extensions for its premium jack-up drilling rigs "Ran", "Gerd" and "Natt". These awards increase the company's firm backlog by approximately 625 days, excluding unexercised optional periods. The premium jack-up drilling rig "Ran" has secured a contract with Fieldwood Energy for work in Mexico. This contract will cover a firm scope of two wells with an estimated duration of 50 days, and one optional well with an estimated duration of 75 days. The firm work has an estimated contract value of $7.5M, excluding mobilization and demobilization. The contract is expected to commence in June in direct continuation of the rig's ongoing contact, and is expected to keep the rig contracted until Q4 when it will start its subsequent contract, as previously disclosed by the company. The premium jack-up drilling rig "Gerd" had certain priced and unpriced options exercised by Addax, extending the contract by a total period of ten months. This extension is expected to maintain the rig contracted until the end of January 2024 and has an estimated contract value of $40M. No further options are available under this contract. Lastly, the premium jack-up drilling rig "Natt" had three well options exercised by ENI, extending he contract by an estimated period of 270 days. This extension is expected to maintain the rig contracted until Q1 2024 and has an estimated contract value of $22.7M.

07:07 EST Tilray's Good Supply cannabis brand launches new product lineup - Tilray Brands announced the expansion of their Good Supply cannabis brand portfolio and the launch of their latest flower campaign. The brand's latest product releases include larger packs of pre-rolls, new pre-roll strains, and new hash and milled flower products, available in select provinces across Canada. Good Supply's latest product lineup includes: Orange Frosting Flower: Full of orange and floral aromas thanks to its rich and unique terpene profile, this new Sativa-leaning Hybrid delivers on uplifting enjoyment. Available in Ontario only in 14g. Daily Grind Milled Flower: The Daily Grind was designed to be as easy as it gets, because let's face it, life is hard. Whole flower buds are milled to be a consistent and versatile size. Available in Alberta in 30g, and Ontario, Manitoba and Saskatchewan in 14g. Party Pack Pre-Rolls: Created for the convenience of the daily cannabis user, Good Supply's new 10 and 14 pack pre-rolls are available in Sweet Berry Kush and Orange Frosting strains. Available in Ontario, Alberta, Manitoba, and Saskatchewan. Watermelon Pre-rolls: A new pre-roll strain that's full of flavour. Relax with this well-rounded Indica, featuring a medley of dominant caryophyllene, humulene and myrcene terpenes. Available for a limited time only in British Columbia, Manitoba and Saskatchewan as a 3x0.5g pre-roll offering. Temple Ball Hash: Old world meets new with this Nepalese-style Temple Ball Hash. A hand-rolled 2g ball with a shiny, dark brown exterior, and potent THC. Break it open and it oozes aromatics that complement its colour and texture. You might even say we're bringing Temple Ball Hash back to the future. Available in Ontario, Alberta, Manitoba and Saskatchewan.

07:05 EST Roivant Sciences announces major upcoming milestones - Major Upcoming Milestones: Roivant plans to announce data from the chronic therapy period of the ongoing TUSCANY-2 study of RVT-3101 for ulcerative colitis in the first half of calendar year 2023. Dermavant expects to report topline data from the first Phase 3 trial of VTAMA for the treatment of atopic dermatitis in March 2023, with topline data from the second Phase 3 trial expected in May 2023. Immunovant plans to initiate a Phase 1 clinical trial for IMVT-1402 in early calendar year 2023 contingent on clearance of its Investigational New Drug application, with initial data results from this Phase 1 trial expected to be available in mid-calendar year 2023. Immunovant expects to have top-line results from the ongoing MG trial in the second half of calendar year 2024 and from the TED program, consisting of two Phase 3 clinical trials, in the first half of calendar year 2025. Immunovant also expects initial data from period 1 of the Phase 2B trial in CIDP to be available in the first half of calendar year 2024. Immunovant expects to initiate a Phase 2 clinical trial to evaluate batoclimab for the treatment of Graves' disease in early calendar year 2023 with initial results expected in the second half of calendar year 2023. Priovant plans to announce topline results from the potentially registrational trial evaluating brepocitinib for the treatment of patients with SLE in the fourth quarter of calendar year 2023. Priovant also expects to announce topline results from the Phase 3 trial in DM in calendar year 2025. Hemavant plans to announce data from the ongoing open-label Phase 1/2 trial evaluating RVT-2001 for the treatment of transfusion-dependent anemia in lower-risk MDS patients in the second half of calendar year 2023. Kinevant plans to report topline data from the ongoing Phase 2 trial of namilumab for the treatment of sarcoidosis in the first half of calendar year 2024.

07:04 EST Steakholder Foods announces patent approval in Canada - Steakholder Foods is proud to announce that it has received approval for its patent on Physical Manipulation of Cultured Muscle Tissue in Canada. This patent, which has already been granted in the US, Australia, and New Zealand, covers systems and methods for applying external forces to muscle tissue, resulting in the development of high-quality complex structured meat.

07:02 EST First National Corporation raises quarterly dividend 7% to 15c per share - The Board of Directors of First National Corporation declared a quarterly cash dividend of $0.15 per share on February 8, 2023. This was a 7% increase compared to the quarterly dividend paid on December 16, 2022. The dividend is payable on March 10, 2023, to shareholders of record as of February 24, 2023.

07:02 EST AxoGen appoints Jens Schroeder Kemp as CMO - Axogen announced the appointment of Jens Schroeder Kemp to the newly created role of Chief Marketing Officer. As a member of the Axogen executive leadership team, Kemp will report directly to Karen Zaderej, Chairman, CEO and President, and will oversee the development and execution of the company's marketing strategies. Mr. Kemp most recently served as Vice President of Marketing for Ambu Inc, where he led Ambu's marketing efforts to create the single use endoscopy market across multiple clinical applications.

06:58 EST Bally's CEO Lee Fenton to step down, Robeson Reeves to succeed - Bally's announced that Lee Fenton, CEO, will step down and Robeson Reeves, president - interactive, will take over as CEO, effective March 31. Fenton became CEO of Bally's on October 1, 2021 following the acquisition of Gamesys Group PLC where he had been CEO since 2015. Fenton will also step down from the Bally's board of directors.

06:43 EST Sanofi Global Head of R&D leaving company to pursue new opportunity - Sanofi announced that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi. "The company warmly thanks Dr. Reed for his leadership over these last years. Since joining Sanofi in 2018, John has laid the foundation for the company's R&D transformation. He helped reshape Sanofi's discovery and development of therapeutics, focusing efforts on first and best in class medicines that have the potential to transform the practice of medicine and improve the lives of people with serious diseases, whilst managing the integration and development of new technology platforms and partnerships, and driving R&D productivity. In 2023, Sanofi will launch two first or best-in-class medicines that will address major needs in hemophilia and respiratory syncytial virus. The company expects in the next 15 months 27 scientific readouts and two pivotal readouts in multiple sclerosis and COPD/chronic bronchitis, also within this year. A clear step forward in Sanofi's scientifically-driven roadmap. While an internal and external search has already started to identify the successor to Dr. Reed, Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim. Dr. Berger has been serving as Chief Medical Officer and Global Head of Development since he joined Sanofi in 2019, after an extensive and successful career at various other pharmaceutical companies including Genentech, Bayer and Amgen," the company stated.

06:35 EST B2Gold announces acquisition of Sabina Gold & Silver - B2Gold and Sabina Gold & Silver announced that the parties have entered into a definitive agreement pursuant to which B2Gold has agreed to acquire all of the issued and outstanding shares of Sabina. The Transaction will result in B2Gold acquiring Sabina's 100% owned Back River Gold District located in Nunavut, Canada. The Back River Gold District consists of five mineral claims blocks along an 80 kilometre belt. The most advanced project in the district, Goose, is fully permitted, construction ready, and has been de-risked with significant infrastructure currently in place. B2Gold has strong northern construction expertise and experience to deliver the fully permitted Goose project and the financial resources to develop the significant gold resource endowment at the Back River Gold District into a large, long life mining complex. Under the terms of the Transaction, B2Gold will issue 0.3867 of a common share of B2Gold for each Sabina common share held, representing consideration of C$1.87 per Sabina Share on a fully-diluted basis and a total equity value for Sabina of approximately C$1.1B based on the closing price of B2Gold on the Toronto Stock Exchange as of February 10. The consideration implies a premium of 45% to the 20-day volume weighted average prices of each of B2Gold and Sabina on the TSX as of February 10, 2023. Furthermore, the consideration implies a premium of 45% to the closing price of Sabina on the TSX as of February 2, 2023, the date the non-binding letter of intent was signed.

06:32 EST Movella announces trading of common stock on Nasdaq Global Market - Movella Holdings will begin trading its common stock and warrants on the Nasdaq Global Market under the ticker symbols "MVLA" and "MVLAW", respectively, February 13, following its successful merger with Pathfinder Acquisition Corp., on Feb. 10.

06:30 EST G1 Therapeutics falls 33% to $4.75 after discontinuing phase 3 PRESERVE 1 trial

06:08 EST Community Healthcare CEO Timothy Wallace to take medical leave - Community Healthcare announced that Timothy Wallace is taking a medical leave of absence from his roles as chairman of the board, CEO and president of the company, effective as of February 10 due to complications from a peptic ulcer. The board of directors has appointed David Dupuy, the company's executive VP and CFO, as interim CEO, effective as of February 10.

06:06 EST Opthea announces publication of Phase 2b trial results of OPT-302 - Opthea announced that the Phase 2b study results of OPT-302, the company's anti-VEGF-C/-D "trap" agent administered in combination with Lucentis for the treatment of wet age-related macular degeneration, have been published online in Ophthalmology, the journal of the American Academy of Ophthalmology. The prospective, randomized, controlled Phase 2b trial of 366 treatment-naive patients with wet AMD, conducted at 109 clinical sites across the United States, Europe and Israel, demonstrated that monthly intravitreal administration of 2.0 mg OPT-302 with ranibizumab standard of care, met the pre-specified primary efficacy endpoint of a statistically superior gain in visual acuity at 24 weeks, compared to ranibizumab alone. In addition, secondary outcomes were positive for the OPT-302 combination therapy including more participants with gains in vision of 10 or more letters, improved anatomy of reduction in swelling and vascular leakage, with a favorable safety profile.

06:04 EST Banc of California raises dividend 67%, announces $35M share buyback program - Banc of California announced that its Board of Directors has declared a quarterly cash dividend of 10c per share on its outstanding common stock. This dividend represents an increase of 4c per share, or 66.7%, over the dividend paid in the previous quarter. The dividend will be payable on April 3 to stockholders of record as of March 15. The company also announced that its Board of Directors has authorized the repurchase of up to $35M of the company's common stock.

06:02 EST Insulet acquires insulin pump patents from Bigfoot Biomedical for $25M - Insulet and Bigfoot Biomedical announced Insulet has acquired assets related to Bigfoot's pump-based automated insulin delivery technologies. Insulet paid $25M for the acquisition, which includes certain Bigfoot patents related to pumps that may be used for AID therapy. The transaction further strengthens Insulet's intellectual property portfolio and provides Bigfoot with additional capital to expand its Bigfoot Unity Diabetes Management System to more people in need of connected insulin injection support technologies. The transaction also includes fully paid-up licenses between the parties in their respective business fields with respect to the acquired patents and other Bigfoot patents.

05:28 EST Futu Holdings announces connectivity, market data partnership with BOT in China - Blue Ocean Technologies, or BOT, the holding company of Blue Ocean ATS; and Futu Clearing, the U.S.-based clearing and execution subsidiary of Futu Holdings announced a connectivity and market data partnership. The new partnership allows Futubull platform clients to electronically trade US National Market System, or NMS, stocks during local business hours in Hong Kong, effective February 13. Furthermore, Blue Ocean is offering Futubull clients market data as part of their integrated investor data offering on its proprietary one-stop digital platform. For the first time Futu is providing clients access to trade U.S. equities in real-time and access market data during Hong Kong local business hours via the Blue Ocean Alternative Trading System market center. The Blue Ocean ATS platform offers Asia-Pacific based investors the ability to trade during 10:00 am to 6:00 pm in Hong Kong. Blue Ocean ATS currently offers all trading subscribers the option to trade via its marquis service Blue Ocean Session from 8:00 pm to 4:00 am U.S. ET.

05:23 EST WISeKey files registration statement to effect partial spin-off of Sealsq Corp - WISeKey announced that, through a wholly-owned subsidiary, Sealsq Corp, it has publicly filed a registration statement on Form F-1 pursuant to the Securities Act of 1933 with the U.S. Securities and Exchange Commission to effect a partial spin-off of Sealsq Corp, currently a wholly-owned subsidiary that acts as the holding company for our semiconductor business. Sealsq is in the process of applying to have its Ordinary Shares listed on the Nasdaq Global Market under the ticker symbol (LAES). WISeKey proposes to distribute 20% of Sealsq's outstanding ordinary shares, to holders of WISeKey Class B Shares, including holders of WISeKey ADSs, and to holders of WISeKey Class A Shares, in each case as a partial spin-off distribution as a dividend in kind to such holders. WISeKey will initially retain 100% ownership of Sealsq's Class F Shares. The transaction is expected to be completed around the beginning of the second quarter of 2023, and remains subject to the applicable approvals and conditions to the transaction being satisfied or waived, including but not limited to, the Form F-1 being declared effective by the SEC, the approval of the listing of Sealsq Ordinary Shares on the Nasdaq Global Market and the approval of the spin-off distribution by the WISeKey shareholders at an Extraordinary General Meeting. There can be no assurance that the transaction will occur, or if one does, its terms or timing. SEALSQ is dedicated to advancing the field of post-quantum computing, making it accessible to a wide range of industries that are already using our semiconductors, and it is enabling advances in communications, computing, healthcare, military systems, transportation, clean energy, and countless other applications.

05:04 EST Check Point announces $2B expansion of share repurchase program - Check Point announced that its board of directors has authorized a $2B expansion of the company's on-going share repurchase program. Under the extended share repurchase program, Check Point is authorized to continue repurchasing its shares up to $325M each quarter.